These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 26279325)
1. Myeloperoxidase Inhibitors as Potential Drugs. Lazarević-Pasti T; Leskovac A; Vasić V Curr Drug Metab; 2015; 16(3):168-90. PubMed ID: 26279325 [TBL] [Abstract][Full Text] [Related]
2. Myeloperoxidase: a target for new drug development? Malle E; Furtmüller PG; Sattler W; Obinger C Br J Pharmacol; 2007 Nov; 152(6):838-54. PubMed ID: 17592500 [TBL] [Abstract][Full Text] [Related]
3. The development of myeloperoxidase inhibitors. Galijasevic S Bioorg Med Chem Lett; 2019 Jan; 29(1):1-7. PubMed ID: 30466896 [TBL] [Abstract][Full Text] [Related]
4. The Role of Myeloperoxidase in Biomolecule Modification, Chronic Inflammation, and Disease. Davies MJ; Hawkins CL Antioxid Redox Signal; 2020 May; 32(13):957-981. PubMed ID: 31989833 [No Abstract] [Full Text] [Related]
5. Reactions and reactivity of myeloperoxidase-derived oxidants: differential biological effects of hypochlorous and hypothiocyanous acids. Pattison DI; Davies MJ; Hawkins CL Free Radic Res; 2012 Aug; 46(8):975-95. PubMed ID: 22348603 [TBL] [Abstract][Full Text] [Related]
7. Reactions of myeloperoxidase-derived oxidants with biological substrates: gaining chemical insight into human inflammatory diseases. Pattison DI; Davies MJ Curr Med Chem; 2006; 13(27):3271-90. PubMed ID: 17168851 [TBL] [Abstract][Full Text] [Related]
8. A patent review of myeloperoxidase inhibitors for treating chronic inflammatory syndromes (focus on cardiovascular diseases, 2013-2019). Soubhye J; Van Antwerpen P; Dufrasne F Expert Opin Ther Pat; 2020 Aug; 30(8):595-608. PubMed ID: 32510253 [TBL] [Abstract][Full Text] [Related]
9. Analysis of the mechanism by which tryptophan analogs inhibit human myeloperoxidase. Sliskovic I; Abdulhamid I; Sharma M; Abu-Soud HM Free Radic Biol Med; 2009 Oct; 47(7):1005-13. PubMed ID: 19596067 [TBL] [Abstract][Full Text] [Related]
10. Myeloperoxidase: a leukocyte-derived protagonist of inflammation and cardiovascular disease. Nussbaum C; Klinke A; Adam M; Baldus S; Sperandio M Antioxid Redox Signal; 2013 Feb; 18(6):692-713. PubMed ID: 22823200 [TBL] [Abstract][Full Text] [Related]
11. Discovery and structure activity relationships of 7-benzyl triazolopyridines as stable, selective, and reversible inhibitors of myeloperoxidase. Shaw SA; Vokits BP; Dilger AK; Viet A; Clark CG; Abell LM; Locke GA; Duke G; Kopcho LM; Dongre A; Gao J; Krishnakumar A; Jusuf S; Khan J; Spronk SA; Basso MD; Zhao L; Cantor GH; Onorato JM; Wexler RR; Duclos F; Kick EK Bioorg Med Chem; 2020 Nov; 28(22):115723. PubMed ID: 33007547 [TBL] [Abstract][Full Text] [Related]
12. Rational drug design applied to myeloperoxidase inhibition. Van Antwerpen P; Zouaoui Boudjeltia K Free Radic Res; 2015 Jun; 49(6):711-20. PubMed ID: 25788127 [TBL] [Abstract][Full Text] [Related]
13. Myeloperoxidase: molecular mechanisms of action and their relevance to human health and disease. van der Veen BS; de Winther MP; Heeringa P Antioxid Redox Signal; 2009 Nov; 11(11):2899-937. PubMed ID: 19622015 [TBL] [Abstract][Full Text] [Related]
14. Acetaminophen (paracetamol) inhibits myeloperoxidase-catalyzed oxidant production and biological damage at therapeutically achievable concentrations. Koelsch M; Mallak R; Graham GG; Kajer T; Milligan MK; Nguyen LQ; Newsham DW; Keh JS; Kettle AJ; Scott KF; Ziegler JB; Pattison DI; Fu S; Hawkins CL; Rees MD; Davies MJ Biochem Pharmacol; 2010 Apr; 79(8):1156-64. PubMed ID: 19968966 [TBL] [Abstract][Full Text] [Related]
15. Small molecule and macrocyclic pyrazole derived inhibitors of myeloperoxidase (MPO). Hu CH; Neissel Valente MW; Halpern OS; Jusuf S; Khan JA; Locke GA; Duke GJ; Liu X; Duclos FJ; Wexler RR; Kick EK; Smallheer JM Bioorg Med Chem Lett; 2021 Jun; 42():128010. PubMed ID: 33811992 [TBL] [Abstract][Full Text] [Related]
16. The soluble curcumin derivative NDS27 inhibits superoxide anion production by neutrophils and acts as substrate and reversible inhibitor of myeloperoxidase. Franck T; Aldib I; Zouaoui Boudjeltia K; Furtmüller PG; Obinger C; Neven P; Prévost M; Soubhye J; Van Antwerpen P; Mouithys-Mickalad A; Serteyn D Chem Biol Interact; 2019 Jan; 297():34-43. PubMed ID: 30342014 [TBL] [Abstract][Full Text] [Related]
17. Thiocyanate catalyzes myeloperoxidase-initiated lipid oxidation in LDL. Exner M; Hermann M; Hofbauer R; Hartmann B; Kapiotis S; Gmeiner B Free Radic Biol Med; 2004 Jul; 37(2):146-55. PubMed ID: 15203186 [TBL] [Abstract][Full Text] [Related]
18. Myeloperoxidase - A bridge linking inflammation and oxidative stress with cardiovascular disease. Ndrepepa G Clin Chim Acta; 2019 Jun; 493():36-51. PubMed ID: 30797769 [TBL] [Abstract][Full Text] [Related]
19. Myeloperoxidase in the inflamed colon: A novel target for treating inflammatory bowel disease. Chami B; Martin NJJ; Dennis JM; Witting PK Arch Biochem Biophys; 2018 May; 645():61-71. PubMed ID: 29548776 [TBL] [Abstract][Full Text] [Related]
20. Regulation of the nitric oxide oxidase activity of myeloperoxidase by pharmacological agents. Maiocchi SL; Morris JC; Rees MD; Thomas SR Biochem Pharmacol; 2017 Jul; 135():90-115. PubMed ID: 28344126 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]